|
Results of the completed phase I trial show:
1. The technology works!
2. We have proven that a recombinant gene in a safe vector can be directly instilled into a local, targeted organ of a human to create a tissue specific, physiological, long-lasting effect without significant transfer related side effects.
There is a significant difference between conventional viral based gene therapy and the Ion Channel Innovations technique. First, because we are targeting organ-specific problems, not cancer or inherited problems, every cell of the target organ or tissue does not have to be altered. Thus, we can use the safest known vector to effect the gene transfer. hMaxi-K uses a “naked,” non-viral human cDNA.
|